However, significant translational barriers remain: no human pharmacokinetic data, high synthesis cost, unknown long-term safety, and the absence of clinical trials
These should encompass well-designed in vitro and in vivo studies alongside large-scale, multicenter randomized controlled trials with extended follow-up periods, diverse patient populations, and standardized dosing and formulation strategies
CrossRef A Newly Synbiotic Combination Alleviates Obesity by Modulating the Gut MicrobiotaFat Axis and Inhibiting the Hepatic TLR4/NFB Signaling Pathway Yongbo Kang, Peng Ren, Xiaorong Shen, Xiaoyu Kuang, Xiaodan Yang, Haixia Liu, Huan Yan, Hao Yang, Xing Kang, Zeyuan Ding, Xuguang Luo, Jieqiong Ma, Ying Yang, Weiping Fan Molecular Nutrition & Food Research.2023;[Epub] CrossRef Lacticaseibacillus paracasei AO356 ameliorates obesity by regulating adipogenesis and thermogenesis in C57BL/6J male mice Young In Kim, Eun-Sook Lee, Eun-Ji Song, Dong-Uk Shin, Ji-Eun Eom, Hee Soon Shin, Jung Eun Kim, Ju Yeoun Oh, Young-Do Nam, So-Young Lee Journal of Functional Foods.2023
Balkesir niversitesi Fen Bilimleri Enstits Dergisi